Skip to Content

Rapastinel Approval Status

Rapastinel (GLYX-13) is a novel NMDA receptor modulator in clinical development as an intravenous adjunctive therapy for major depressive disorder (MDD).

Development Status and FDA Approval Process for rapastinel

Mar  3, 2014FDA Grants Fast Track Designation to Naurex's Rapid-Acting Novel Antidepressant GLYX-13

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.